Prognostic and Immunological Role of RBMX in cancers

preprint OA: closed
View at publisher

Abstract

Cancer, as the disease causing the highest morbidity and mortality worldwide, attracted all kinds of research investment but received little effect. RBMX, a nuclear RNA binding protein, verified to associated with certain types of cancer through participating in integration of sister chromatids and combination of ribonucleoprotein complex. However, the specific role of RBMX in pan-cancer remains unknown. This article presents the robust role of RBMX in predicting the immunotherapy response and screening the effective prognostic biomarker for cancer therapy. Here, we did comprehensive of RBMX using the sample from the Genotype-Tissue Expression (GTEx) datasets and TCGA pan-cancer cohort. We present experimentally that RBMX’s independent role in prediction and diagnosis. In the future, RBMX blocking-up may become a novel method in cancer therapy.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00